US FDA ‘Punt’ On Hemp Rulemaking Frustrates, Confuses Supplement Industry
Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.
You may also be interested in...
Bill Steering Hemp In Supplements To NDI Notification Pathway Introduced For Third Time
Virginia Republican Morgan Griffith has same message for FDA he’s previously stated about hemp ingredients. Agency “has dragged its feet in properly regulating CBD and hemp-derived products on the market, creating confusion about its legal uses,” he says.
CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request
Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.
As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance
Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.